October 28, 2011

**Bombay Stock Exchange Limited,**
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
**MUMBAI - 400 001.**

**Dear Sirs,**

**Sub: Disclosure pursuant to Clause 36 of the Listing Agreement.**

Enclosed is a press release as regards receipt of final US FDA approval for the Company's Abbreviated New Drug Application (ANDA) for its Levonorgestrel and Ethinyl Estradiol Tablets 0.1 mg /0.02 mg and Ethinyl Estradiol Tablets 0.01 mg.

This may be considered as the disclosure pursuant to Clause 36 of the Listing Agreement.

Thanking you,

Yours faithfully,
**For LUPIN LIMITED**

**R. V. SATAM**
**COMPANY SECRETARY & COMPLIANCE OFFICER**

**Encl.: a/a.**

October 28, 2011

**The National Stock Exchange of India Ltd.,**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
**MUMBAI - 400 051.**

**Dear Sirs,**

**Sub: Disclosure pursuant to Clause 36 of the Listing Agreement.**

Enclosed is a press release as regards receipt of final US FDA approval for the Company's Abbreviated New Drug Application (ANDA) for its Levonorgestrel and Ethinyl Estradiol Tablets 0.1 mg /0.02 mg and Ethinyl Estradiol Tablets 0.01 mg.

This may be considered as the disclosure pursuant to Clause 36 of the Listing Agreement.

Thanking you,

Yours faithfully,
**For LUPIN LIMITED**

**R. V. SATAM**
**COMPANY SECRETARY & COMPLIANCE OFFICER**

**Encl.: a/a.**

| BSE : 500257 | NSE: Lupin | REUTERS: LUPN.BO | BLOOMBERG: LPC IN |
|---|---|---|---|

# Lupin receives Final FDA Approval for Generic LoSeasonique® Tablets

**Mumbai / Baltimore, October 28, 2011**: Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (LPI) has received final approval for its Levonorgestrel and Ethinyl Estradiol Tablets 0.1 mg /0.02 mg and Ethinyl Estradiol Tablets 0.01 mg from the U.S. Food and Drug Administration (FDA) for the company's Abbreviated New Drug Application (ANDA) to market a generic version of Teva Women's Health, Inc's. LoSeasonique® Tablets.

Lupin believes that it is one of the first applicants to file an ANDA for LoSeasonique® Tablets and will be entitled to 180 days of marketing exclusivity.

Commenting on the launch, Nilesh Gupta, Group President of Lupin said, "We are very happy to receive this approval. This product approval demonstrates our commitment to deliver a quality Oral Contraceptive pipeline to consumers in the U.S., built around our development and vertically integrated manufacturing strengths. Consumers can be assured they are receiving quality products that they have been accustomed to, at a more affordable price".

**About Lupin Limited**

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs. The Company today has significant market share in Cardiovasculars, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs in addition holding global leadership positions in the Anti-TB and Cephalosporins space.

Today, Lupin is the 5th largest and fastest growing generics player in the US (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa. (IMS Health)

For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs.57,068 million (USD 1.28 Billion) and Rs. 8,626 million (USD 193 million) respectively. Please visit http://www.lupinworld.com for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com.

For further information please contact:

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited:
Ph: +91 98 20 338 555
Email: shamshergorawara@lupinpharma.com or

Sonia Mansata
Text 100 Public Relations
Ph: +91 98 20 11 2481
Email: sonia.mansata@text100.co.in

*Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:*
*This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release*

* *LoSEASONIQUE® is a registered trademark of Teva Women's Health, Inc.*